Aravive, Inc. (ARAV)

1 member of Congress has disclosed 2 trades in Aravive, Inc. (ARAV) via STOCK Act filings. The most recent disclosure was a sale by Bob Gibbs on 28 December 2018.

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Past Performance is not an indication of future results.

Price data is not available for ARAV
This ticker may have been delisted, renamed, or is not publicly quoted, so no live price, statistics or chart can be shown. The congressional trades disclosed for it are listed below.

Congressional Trading Activity for ARAV

2 transactions
Compliance: 50%
Bob Gibbs28 Dec 201813 Jan 2019SaleStock$158.65N/A
Bob Gibbs28 Dec 20183 May 2019SaleStock$158.65N/A

Stock Overview

Market Data

Market Cap

$2.95M

Volume

4.04M

Beta

2.19

P/E Ratio

-0.05

Fundamentals

EPS

$-0.76

Div. Yield

-

Open

$0.04

Day Range

$0.04 – $0.05

Company Information

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ · USD
Country
US
CEO
Fredric N. Eshelman
IPO Date
2014-03-21

Aravive, Inc. is a clinical-stage biopharmaceutical company, based in Houston, Texas, dedicated to discovering and developing innovative treatments for life-threatening illnesses such as cancer and fibrosis. The company's primary therapeutic candidat...

Earnings

Recent Quarters

Q4 202320 Mar
EPS$-0.46
Miss 475.0%
Q3 20239 Nov
EPS$-0.10
Beat 58.3%
Q2 202321 Aug
EPS$-0.12
Beat 60.0%
Q1 202311 May
EPS$-0.66
Miss 100.0%
Q4 202215 Mar
EPS$-0.46
Miss 39.4%
Q3 202210 Nov
EPS$-0.51
Beat 20.3%
Q2 202211 Aug
EPS$-0.61
Beat 1.6%
Q1 202212 May
EPS$-0.62
Miss 17.0%
Q4 202131 Mar
EPS$-0.62
Beat 3.1%
Q3 202128 Oct
EPS$-0.53
Miss 26.2%
Q2 20215 Aug
EPS$-0.35
Beat 14.6%
Q1 20216 May
EPS$-0.44
Beat 2.2%
Q4 202016 Mar
EPS$-0.25
Beat 51.9%
Q3 20205 Nov
EPS$-0.66
Miss 57.1%
Q2 20203 Aug
EPS$-0.32
Beat 28.9%
Q1 20206 May
EPS$-0.53
Miss 55.9%
Q4 201927 Mar
EPS$-0.35
Beat 34.0%
Q3 20197 Nov
EPS$-0.54
Miss 8.0%
Q2 20197 Aug
EPS$-0.27
Beat 51.8%
Q1 20198 May
EPS$-0.42
Beat 46.8%
Q4 20187 Mar
EPS$-1.20
Q3 20186 Nov
EPS$-1.08
Q2 20187 Aug
EPS$-1.62
Beat 71.9%
Q1 20188 May
EPS$-1.50
Beat 70.9%
Q4 20171 Mar
EPS$5.22
Beat 193.4%
Q3 201726 Oct
EPS$-8.40
Miss 98.1%
Q2 201727 Jul
EPS$-6.24
Miss 23.1%
Q1 201727 Apr
EPS$-5.10
Miss 17.5%
Q4 201621 Feb
EPS$-3.84
Miss 4.1%
Q3 20163 Nov
EPS$-5.52
Miss 258.4%
Q2 201628 Jul
EPS$-4.50
Beat 11.1%
Q1 201628 Apr
EPS$-4.92
Miss 8.1%
Q4 201518 Feb
EPS$-4.14
Beat 2.8%
Q3 201529 Oct
EPS$-4.14
Beat 2.6%
Q2 20154 Aug
EPS$-4.02
Miss 5.5%
Q1 20156 May
EPS$-4.74
Miss 26.1%
Q4 201412 Feb
EPS$-3.90
Miss 47.7%
Q3 20146 Nov
EPS$-3.42
Miss 7.5%
Q2 20145 Aug
EPS$-2.16
Beat 19.1%
Q1 201414 May
EPS$-41.81
Q1 20145 May
EPS$-56.64
Miss 48.2%
Q2 201330 Sept
EPS$-119.86
Q1 201330 Jun
EPS$-148.47
Q4 201231 Mar
EPS$-181.35
Q3 201231 Dec
EPS$-1.01

No dividend data available for this stock.

Stock Splits

Split History

16 Oct 2018Reverse Split
Ratio1:6

Similar Stocks

Based on congressional trading patterns

Smart Recommendations
No similar stocks found
No congressional trading patterns available for recommendations

Frequently Asked Questions about ARAV

Which members of Congress have traded ARAV?
1 member of Congress has disclosed 2 trade in Aravive, Inc. (ARAV) under the STOCK Act: Bob Gibbs.
When was ARAV most recently disclosed by Congress?
The most recent ARAV disclosure was a sale by Bob Gibbs on 28 December 2018.
How can I track new congressional trades in ARAV?
This ARAV page updates as soon as new STOCK Act disclosures are filed for Aravive, Inc.. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
© 2026 - All rights reserved. Powered by Vantara Labs
Pelosi Tracker is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office or her representatives, or with any other member of Congress. Any use of her name is solely for the purpose of discussing publicly available information.The information provided by Pelosi Tracker is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.